恆瑞醫藥(600276.SH)半年度淨利潤升10.34%至26.62億元
格隆匯 7 月 31日丨恆瑞醫藥(600276.SH)披露2020年半年報,實現營業收入113.09億元,同比增長12.79%;歸屬於上市公司股東的淨利潤26.62億元,同比增長10.34%;歸屬於上市公司股東的扣除非經常性損益的淨利潤25.62億元,同比增長11.94%;基本每股收益0.50元。經營活動產生的現金流量淨額33.77億元,同比增長132.47%。
報告期內累計研發投入18.63億元,同比增長25.56%,研發投入佔銷售收入的比重達到16.48%,有力地支持了公司的項目研發和創新發展。二是項目註冊申報有序推進。報告期內公司取得創新藥製劑生產批件3個,仿製藥製劑生產批件1個,取得創新藥臨牀批件37個,取得3個品種的一致性評價批件,完成2種產品的一致性評價申報工作。三是專利申請和維持工作順利開展。報告期內公司提交國內新申請專利78件,提交國際PCT新申請39件,獲得國內授權24件,獲得國外授權49件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.